AAAAAA

   
Results: 1-25 | 26-37
Results: 1-25/37
A PHASE-I AND TRANSLATIONAL STUDY OF SEQUENTIAL ADMINISTRATION OF THETOPOISOMERASE-I AND TOPOISOMERASE-II INHIBITORS TOPOTECAN AND ETOPOSIDE
Authors: HAMMOND LA ECKARDT JR GANAPATHI R BURRIS HA RODRIGUEZ GA ECKHARDT SG ROTHENBERG ML WEISS GR KUHN JG HODGES S VONHOFF DD ROWINSKY EK
Citation: La. Hammond et al., A PHASE-I AND TRANSLATIONAL STUDY OF SEQUENTIAL ADMINISTRATION OF THETOPOISOMERASE-I AND TOPOISOMERASE-II INHIBITORS TOPOTECAN AND ETOPOSIDE, Clinical cancer research, 4(6), 1998, pp. 1459-1467
PHASE-I AND PHARMACOKINETIC STUDY OF GI147211, A WATER-SOLUBLE CAMPTOTHECIN ANALOG, ADMINISTERED FOR 5 CONSECUTIVE DAYS EVERY 3 WEEKS
Authors: ECKHARDT SG BAKER SD ECKARDT JR BURKE TG WARNER DL KUHN JG RODRIGUEZ G FIELDS S THURMAN A SMITH L ROTHENBERG ML WHITE L WISSEL P KUNKA R DEPEE S LITTLEFIELD D BURRIS HA VONHOFF DD ROWINSKY EK
Citation: Sg. Eckhardt et al., PHASE-I AND PHARMACOKINETIC STUDY OF GI147211, A WATER-SOLUBLE CAMPTOTHECIN ANALOG, ADMINISTERED FOR 5 CONSECUTIVE DAYS EVERY 3 WEEKS, Clinical cancer research, 4(3), 1998, pp. 595-604
PHASE-I AND PHARMACOKINETIC STUDY OF GI147211, A WATER-SOLUBLE CAMPTOTHECIN ANALOG, ADMINISTERED FOR 5 CONSECUTIVE DAYS EVERY 3 WEEKS
Authors: ECKHARDT SG BAKER SD ECKARDT JR BURKE TG WARNER DL KUHN JG RODRIGUEZ G FIELDS S THURMAN A SMITH L ROTHENBERG ML WHITE L WISSEL P KUNKA R DEPEE S LITTLEFIELD D BURRIS HA VONHOFF DD ROWINSKY EK
Citation: Sg. Eckhardt et al., PHASE-I AND PHARMACOKINETIC STUDY OF GI147211, A WATER-SOLUBLE CAMPTOTHECIN ANALOG, ADMINISTERED FOR 5 CONSECUTIVE DAYS EVERY 3 WEEKS, Clinical cancer research, 4(3), 1998, pp. 595-604
A PHASE-I AND PHARMACOLOGICAL STUDY OF THE GLUTAMINE ANTAGONIST ACIVICIN WITH THE AMINO-ACID SOLUTION AMINOSYN IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES
Authors: HIDALGO M RODRIGUEZ G KUHN JG BROWN T WEISS G MACGOVREN JP VONHOFF DD ROWINSKY EK
Citation: M. Hidalgo et al., A PHASE-I AND PHARMACOLOGICAL STUDY OF THE GLUTAMINE ANTAGONIST ACIVICIN WITH THE AMINO-ACID SOLUTION AMINOSYN IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES, Clinical cancer research, 4(11), 1998, pp. 2763-2770
PHASE-I AND PHARMACOKINETIC STUDY OF INTRAVENOUS IRINOTECAN (CPT-11) ADMINISTERED ONCE EVERY 2 WEEKS + - G-CSF/
Authors: ROTHENBERG ML KUHN JG SCHAAF LJ ECKHARDT SG VILLALONACALERO MA PETIT RG MILLER LL ELFRING GL MURPHY TC VONHOFF DD
Citation: Ml. Rothenberg et al., PHASE-I AND PHARMACOKINETIC STUDY OF INTRAVENOUS IRINOTECAN (CPT-11) ADMINISTERED ONCE EVERY 2 WEEKS + - G-CSF/, Annals of oncology, 9, 1998, pp. 240-240
PHARMACOLOGY OF IRINOTECAN
Authors: KUHN JG
Citation: Jg. Kuhn, PHARMACOLOGY OF IRINOTECAN, Oncology, 12(8), 1998, pp. 39-42
ALTERNATIVE DOSING SCHEDULES FOR IRINOTECAN
Authors: ROTHENBERG ML KUHN JG SCHAAF LJ DRENGLER RL ECKHARDT SG VILLALONACALERO MA HAMMOND L MILLER LL PETIT RG ROWINSKY EK VONHOFF DD
Citation: Ml. Rothenberg et al., ALTERNATIVE DOSING SCHEDULES FOR IRINOTECAN, Oncology, 12(8), 1998, pp. 68-71
PHASE-I STUDY OF PACLITAXEL IN PATIENTS WITH RECURRENT MALIGNANT GLIOMA - A NORTH-AMERICAN BRAIN-TUMOR CONSORTIUM REPORT
Authors: CHANG SM KUHN JG RIZZO J ROBINS HI SCHOLD SC SPENCE AM BERGER MS MEHTA MP BOZIK ME POLLACK I GILBERT M FULTON D RANKIN C MALEC M PRADOS MD
Citation: Sm. Chang et al., PHASE-I STUDY OF PACLITAXEL IN PATIENTS WITH RECURRENT MALIGNANT GLIOMA - A NORTH-AMERICAN BRAIN-TUMOR CONSORTIUM REPORT, Journal of clinical oncology, 16(6), 1998, pp. 2188-2194
EVALUATION OF THE LINEARITY OF DOCETAXEL PHARMACOKINETICS
Authors: MCLEOD HL KEARNS CM KUHN JG BRUNO R
Citation: Hl. Mcleod et al., EVALUATION OF THE LINEARITY OF DOCETAXEL PHARMACOKINETICS, Cancer chemotherapy and pharmacology, 42(2), 1998, pp. 155-159
PHARMACOKINETIC AND PHASE-I STUDIES OF BREQUINAR (DUP-785, NSC-368390) IN COMBINATION WITH CISPLATIN IN PATIENTS WITH ADVANCED MALIGNANCIES
Authors: BURRIS HA RAYMOND E AWADA A KUHN JG OROURKE TJ BRENTZEL J LYNCH W KING SYP BROWN TD VONHOFF DD
Citation: Ha. Burris et al., PHARMACOKINETIC AND PHASE-I STUDIES OF BREQUINAR (DUP-785, NSC-368390) IN COMBINATION WITH CISPLATIN IN PATIENTS WITH ADVANCED MALIGNANCIES, Investigational new drugs, 16(1), 1998, pp. 19-27
A PHASE-I AND PHARMACOKINETIC TRIAL OF TEREPHTHALAMIDINE (NSC-57155) AS A 120-HOUR CONTINUOUS-INFUSION
Authors: RODRIGUEZ GI KUHN JG WEISS G DELACRUZ P NEW P FIELDS SM ECKARDT JR CAMPBELL L CLARK GM HILSENBECK SG VONHOFF DD
Citation: Gi. Rodriguez et al., A PHASE-I AND PHARMACOKINETIC TRIAL OF TEREPHTHALAMIDINE (NSC-57155) AS A 120-HOUR CONTINUOUS-INFUSION, Investigational new drugs, 16(1), 1998, pp. 57-67
A BIOAVAILABILITY AND PHARMACOKINETIC STUDY OF ORAL AND INTRAVENOUS HYDROXYUREA
Authors: RODRIGUEZ GI KUHN JG WEISS GR HILSENBECK SG ECKARDT JR THURMAN A RINALDI DA HODGES S VONHOFF DD ROWINSKY EK
Citation: Gi. Rodriguez et al., A BIOAVAILABILITY AND PHARMACOKINETIC STUDY OF ORAL AND INTRAVENOUS HYDROXYUREA, Blood, 91(5), 1998, pp. 1533-1541
A PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF THE ANGIOGENESIS INHIBITOR, TECOGALAN SODIUM
Authors: ECKHARDT SG BURRIS HA ECKARDT JR WEISS G RODRIGUEZ G ROTHENBERG M RINALDI D BARRINGTON R KUHN JG MASUO K SUDO K ATSUMI R OGUMA T HIGASHI L FIELDS S SMETZER L VONHOFF DD
Citation: Sg. Eckhardt et al., A PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF THE ANGIOGENESIS INHIBITOR, TECOGALAN SODIUM, Annals of oncology, 7(5), 1996, pp. 491-496
PHARMACOKINETIC PROFILE OF RECOMBINATION HUMAN INSULIN-LIKE GROWTH-FACTOR BINDING PROTEIN-1 IN ATHYMIC MICE
Authors: YEE D VANDENBERG CL KOZELSKY TW KUHN JG COX GN
Citation: D. Yee et al., PHARMACOKINETIC PROFILE OF RECOMBINATION HUMAN INSULIN-LIKE GROWTH-FACTOR BINDING PROTEIN-1 IN ATHYMIC MICE, Biomedicine & pharmacotherapy, 50(3-4), 1996, pp. 154-157
PHASE-II TRIAL OF IRINOTECAN IN PATIENTS WITH PROGRESSIVE OR RAPIDLY RECURRENT COLORECTAL-CANCER
Authors: ROTHENBERG ML ECKARDT JR KUHN JG BURRIS HA NELSON J HILSENBECK SG RODRIGUEZ GI THURMAN AM SMITH LS ECKHARDT SG WEISS GR ELFRING GL RINALDI DA SCHAAF LJ VONHOFF DD
Citation: Ml. Rothenberg et al., PHASE-II TRIAL OF IRINOTECAN IN PATIENTS WITH PROGRESSIVE OR RAPIDLY RECURRENT COLORECTAL-CANCER, Journal of clinical oncology, 14(4), 1996, pp. 1128-1135
PHARMACOKINETIC PROFILE OF MITOGUAZONE (MGBG) IN PATIENTS WITH AIDS-RELATED NON-HODGKINS-LYMPHOMA
Authors: RIZZO J LEVINE AM WEISS GR PEARCE T KRAYNAK M MUECK R SMITH S VONHOFF DD KUHN JG
Citation: J. Rizzo et al., PHARMACOKINETIC PROFILE OF MITOGUAZONE (MGBG) IN PATIENTS WITH AIDS-RELATED NON-HODGKINS-LYMPHOMA, Investigational new drugs, 14(2), 1996, pp. 227-234
DETECTION OF A POINT MUTATION IN NQO1 (DT-DIAPHORASE) IN A PATIENT WITH COLON-CANCER - RESPONSE
Authors: KOLESAR JM BURRIS HA KUHN JG
Citation: Jm. Kolesar et al., DETECTION OF A POINT MUTATION IN NQO1 (DT-DIAPHORASE) IN A PATIENT WITH COLON-CANCER - RESPONSE, Journal of the National Cancer Institute, 87(23), 1995, pp. 1803-1803
DETECTION OF A POINT MUTATION IN NQO1 (DT-DIAPHORASE) IN A PATIENT WITH COLON-CANCER
Authors: KOLESAR JM KUHN JG BURRIS HA
Citation: Jm. Kolesar et al., DETECTION OF A POINT MUTATION IN NQO1 (DT-DIAPHORASE) IN A PATIENT WITH COLON-CANCER, Journal of the National Cancer Institute, 87(13), 1995, pp. 1022-1024
DEOXYSPERGUALIN - PHASE-I CLINICAL, IMMUNOLOGICAL AND PHARMACOKINETICSTUDY
Authors: HAVLIN KA KUHN JG KOELLER J BOLDT DH CRAIG JB BROWN TD WEISS GR CAGNOLA J PHILLIPS J HARMAN G HARDY J VONHOFF DD
Citation: Ka. Havlin et al., DEOXYSPERGUALIN - PHASE-I CLINICAL, IMMUNOLOGICAL AND PHARMACOKINETICSTUDY, Anti-cancer drugs, 6(2), 1995, pp. 229-236
INITIAL PHASE-I EVALUATION OF THE NOVEL THYMIDYLATE SYNTHASE INHIBITOR, LY231514, USING THE MODIFIED CONTINUAL REASSESSMENT METHOD FOR DOSE
Authors: RINALDI DA BURRIS HA DORR FA WOODWORTH JR KUHN JG ECKARDT JR RODRIGUEZ G CORSO SW FIELDS SM LANGLEY C CLARK G FARIES D LU P VONHOFF DD
Citation: Da. Rinaldi et al., INITIAL PHASE-I EVALUATION OF THE NOVEL THYMIDYLATE SYNTHASE INHIBITOR, LY231514, USING THE MODIFIED CONTINUAL REASSESSMENT METHOD FOR DOSE, Journal of clinical oncology, 13(11), 1995, pp. 2842-2850
PHASE-I AND PHARMACOKINETICS STUDY OF 2-CHLORODEOXYADENOSINE PATIENTSWITH SOLID TUMORS
Authors: WEISS GR KUHN JG RIZZO J SMITH LS RODRIGUEZ GI ECKARDT JR BURRIS HA FIELDS S VANDENBERG K VONHOFF DD
Citation: Gr. Weiss et al., PHASE-I AND PHARMACOKINETICS STUDY OF 2-CHLORODEOXYADENOSINE PATIENTSWITH SOLID TUMORS, Cancer chemotherapy and pharmacology, 35(5), 1995, pp. 397-402
HEPSULFAM DISTRIBUTION IN BLOOD, PLASMA AND CEREBROSPINAL-FLUID OF BABOONS
Authors: MARSHALL MV CAREY KD VONHOFF DD KUHN JG
Citation: Mv. Marshall et al., HEPSULFAM DISTRIBUTION IN BLOOD, PLASMA AND CEREBROSPINAL-FLUID OF BABOONS, Investigational new drugs, 13(1), 1995, pp. 33-36
PHARMACODYNAMICS OF DAILY SUBCUTANEOUS RECOMBINANT HUMAN INTERLEUKIN-3 IN NORMAL VOLUNTEERS
Authors: HUHN RD YURKOW EJ KUHN JG CLARKE L GUNN H RESTA D SHAH R MYERS LA SEIBOLD JR
Citation: Rd. Huhn et al., PHARMACODYNAMICS OF DAILY SUBCUTANEOUS RECOMBINANT HUMAN INTERLEUKIN-3 IN NORMAL VOLUNTEERS, Clinical pharmacology and therapeutics, 57(1), 1995, pp. 32-41
ACTIVITY OF DMP-840, A NEW BIS-NAPHTHALIMIDE, ON PRIMARY HUMAN TUMOR COLONY-FORMING-UNITS
Authors: COBB PW DEGEN DR CLARK GM CHEN SF KUHN JG GROSS JL KIRSHENBAUM MR SUN JH BURRIS HA VONHOFF DD
Citation: Pw. Cobb et al., ACTIVITY OF DMP-840, A NEW BIS-NAPHTHALIMIDE, ON PRIMARY HUMAN TUMOR COLONY-FORMING-UNITS, Journal of the National Cancer Institute, 86(19), 1994, pp. 1462-1465
ACTIVITY OF INTOPLICINE (RP60475), A NEW DNA TOPOISOMERASE-I AND TOPOISOMERASE-II INHIBITOR, AGAINST HUMAN TUMOR COLONY-FORMING-UNITS IN-VITRO
Authors: ECKARDT JR BURRIS HA KUHN JG BISSERY MC KLINKALAKL M CLARK GM VONHOFF DD
Citation: Jr. Eckardt et al., ACTIVITY OF INTOPLICINE (RP60475), A NEW DNA TOPOISOMERASE-I AND TOPOISOMERASE-II INHIBITOR, AGAINST HUMAN TUMOR COLONY-FORMING-UNITS IN-VITRO, Journal of the National Cancer Institute, 86(1), 1994, pp. 30-33
Risultati: 1-25 | 26-37